Last reviewed · How we verify

shofu PRG barrier coat

Cairo University · FDA-approved active Small molecule Quality 5/100

Shofu PRG barrier coat, developed by Cairo University, is a marketed product with a key composition patent expiring in 2028. The drug's primary strength lies in its unique mechanism, which differentiates it from existing treatments. The primary risk is the patent expiry in 2028, which could lead to increased competition from generics.

At a glance

Generic nameshofu PRG barrier coat
Also known asLight cured giomer
SponsorCairo University
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: